Wenjuan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenjuan Liu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Lin-Lin Hu
Sleep Medicine Center, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
3 shared publications - Mingfen Song
Affiliated Mental Health Centre & Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, 310013 Hangzhou, Zhejiang, China
3 shared publications You Xu
Department of Sleep Medicine, Affiliated Mental Health Center, Zhejiang University School of Medicine (Hangzhou Seventh People’s Hospital), Hangzhou, People’s Republic of China
3 shared publicationsCai-E Ma
Department of Sleep Medicine, Affiliated Mental Health Center, Zhejiang University School of Medicine (Hangzhou Seventh People’s Hospital), Hangzhou, People’s Republic of China
2 shared publications- Hongjing Mao
Affiliated Mental Health Center & Hangzhou Seventh People’s Hospital, Zhejiang University School of Medicine, China
2 shared publications Jun-Hang Zhang
Department of Information Science, Affiliated Mental Health Center, Zhejiang University School of Medicine (Hangzhou Seventh People’s Hospital), Hangzhou, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1919011
Narcolepsy-like presentations in intellectual disability with comorbid epilepsy and obstructive sleep apnea: a case-based diagnostic analysis and literature-informed discussion
Excessive daytime sleepiness (EDS), nocturnal impaired-awareness episodes, and abnormal sleep-related behaviors have complex and overlapping etiologies. Narcolepsy, obstructive sleep apnea (OSA), and epileptic nocturnal events may present with similar clinical manifestations. In patients with intellectual disability (ID), restricted self-reporting, incomplete caregiver observations, and diagnostic overshadowing may lead clinicians to misattribute underlying neurological or sleep disorders to preexisting cognitive impairment or psychiatric and behavioral problems, resulting in delayed diagnosis or misdiagnosis. We present an illustrative case of a 34-year-old woman with lifelong cognitive and adaptive impairments who was referred for long-standing snoring, EDS, and two nocturnal impaired-awareness episodes. An outside emergency department had previously considered “sleep apnea?” and “narcolepsy?” as possible diagnoses. After detailed collateral history-taking, overnight polysomnography (PSG), the Multiple Sleep Latency Test (MSLT), and two 24-hour ambulatory electroencephalography (EEG) recordings, she was diagnosed with epilepsy with focal to bilateral tonic-clonic seizures, moderate OSA, and mild ID. At the 6-month follow-up after concurrent initiation of levetiracetam (LEV) and continuous positive airway pressure (CPAP) therapy, no further nocturnal impaired-awareness episodes, limb jerking, or cyanosis of the lips were reported; her EDS also improved, with the Epworth Sleepiness Scale (ESS) score decreasing from 18/24 at baseline to 6/24. Rather than reporting a rare comorbidity alone, this case-based diagnostic analysis uses the index case to clarify the differential diagnostic approach to EDS and nocturnal events in patients with ID, highlights the key distinctions among narcolepsy, OSA-related sleepiness, and epileptic nocturnal events, and emphasizes the need for integrated management when OSA and epilepsy coexist.
- 4 September 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1919011
Open AccessNarcolepsy-like presentations in intellectual disability with comorbid epilepsy and obstructive sleep apnea: a case-based diagnostic analysis and literature-informed discussion
Excessive daytime sleepiness (EDS), nocturnal impaired-awareness episodes, and abnormal sleep-related behaviors have complex and overlapping etiologies. Narcolepsy, obstructive sleep apnea (OSA), and epileptic nocturnal events may present with similar clinical manifestations. In patients with intellectual disability (ID), restricted self-reporting, incomplete caregiver observations, and diagnostic overshadowing may lead clinicians to misattribute underlying neurological or sleep disorders to preexisting cognitive impairment or psychiatric and behavioral problems, resulting in delayed diagnosis or misdiagnosis. We present an illustrative case of a 34-year-old woman with lifelong cognitive and adaptive impairments who was referred for long-standing snoring, EDS, and two nocturnal impaired-awareness episodes. An outside emergency department had previously considered “sleep apnea?” and “narcolepsy?” as possible diagnoses. After detailed collateral history-taking, overnight polysomnography (PSG), the Multiple Sleep Latency Test (MSLT), and two 24-hour ambulatory electroencephalography (EEG) recordings, she was diagnosed with epilepsy with focal to bilateral tonic-clonic seizures, moderate OSA, and mild ID. At the 6-month follow-up after concurrent initiation of levetiracetam (LEV) and continuous positive airway pressure (CPAP) therapy, no further nocturnal impaired-awareness episodes, limb jerking, or cyanosis of the lips were reported; her EDS also improved, with the Epworth Sleepiness Scale (ESS) score decreasing from 18/24 at baseline to 6/24. Rather than reporting a rare comorbidity alone, this case-based diagnostic analysis uses the index case to clarify the differential diagnostic approach to EDS and nocturnal events in patients with ID, highlights the key distinctions among narcolepsy, OSA-related sleepiness, and epileptic nocturnal events, and emphasizes the need for integrated management when OSA and epilepsy coexist.
- Open Access
- 7 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (32) , e50039
The burden of mental disorders, substance use disorders and self-harm among adolescents aged 10 to 19 years from 1990 to 2021 and predictions to 2046 in China: A population-based study
The study aims to assess the mental health burden among Chinese adolescents aged 10 to 19 years via the 2021 Global Burden of Diseases Study (GBD). Data on the disease burden owing to mental health conditions of Chinese adolescents aged 10 to 19 years from 1990 to 2021 were obtained from the GBD 2021. Disability-adjusted life of years, years of life lost (YLLs), years lived with disability (YLDs), and the prevalence rates of mental disorders (MDs), substance use disorders (SUDs) and self-harm were plotted against sociodemographic index from 1990 to 2021. Temporal trends in the disease burden were evaluated using the Joinpoint Regression. The Nordpred model was applied to project the disease burden over the next 25 years. The burdens of MDs, SUDs, and self-harm accounted for 31.3% of total YLDs and 7.1% of total YLLs among Chinese adolescents aged 10 to 19 years in 2021. These conditions contributed 1439 YLDs (average annual percentage change [AAPC] = −0.2, 95% CI: −0.3 to −0.1) and 139 YLLs (AAPC = −5.2, 95% CI: −5.6 to −4.8). Significant increases in YLDs were observed for eating disorders (AAPC = 1.3, 95% CI: 1.2 to 1.4), whereas intellectual disabilities and developmental disorders significantly decreased (AAPC = −1.4, 95% CI: −1.5 to −1.3). Differences were evident across age and sex groups. The burden of SUDs reaches to the lowest point with an sociodemographic index value of 0.68. Among GBD-quantified risk factors, bullying victimization was a major contributor to disability. The burden of MDs and SUDs is projected to continue increasing over the next 25 years. The mental health burden among Chinese adolescents is a leading contributor to disability. Model-based projections suggest increasing future burdens of MDs and SUDs, underscoring the need for regularly updated, age- and sex-specific adolescent mental health policies.
- 7 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (32) , e50039
Open AccessThe burden of mental disorders, substance use disorders and self-harm among adolescents aged 10 to 19 years from 1990 to 2021 and predictions to 2046 in China: A population-based study
The study aims to assess the mental health burden among Chinese adolescents aged 10 to 19 years via the 2021 Global Burden of Diseases Study (GBD). Data on the disease burden owing to mental health conditions of Chinese adolescents aged 10 to 19 years from 1990 to 2021 were obtained from the GBD 2021. Disability-adjusted life of years, years of life lost (YLLs), years lived with disability (YLDs), and the prevalence rates of mental disorders (MDs), substance use disorders (SUDs) and self-harm were plotted against sociodemographic index from 1990 to 2021. Temporal trends in the disease burden were evaluated using the Joinpoint Regression. The Nordpred model was applied to project the disease burden over the next 25 years. The burdens of MDs, SUDs, and self-harm accounted for 31.3% of total YLDs and 7.1% of total YLLs among Chinese adolescents aged 10 to 19 years in 2021. These conditions contributed 1439 YLDs (average annual percentage change [AAPC] = −0.2, 95% CI: −0.3 to −0.1) and 139 YLLs (AAPC = −5.2, 95% CI: −5.6 to −4.8). Significant increases in YLDs were observed for eating disorders (AAPC = 1.3, 95% CI: 1.2 to 1.4), whereas intellectual disabilities and developmental disorders significantly decreased (AAPC = −1.4, 95% CI: −1.5 to −1.3). Differences were evident across age and sex groups. The burden of SUDs reaches to the lowest point with an sociodemographic index value of 0.68. Among GBD-quantified risk factors, bullying victimization was a major contributor to disability. The burden of MDs and SUDs is projected to continue increasing over the next 25 years. The mental health burden among Chinese adolescents is a leading contributor to disability. Model-based projections suggest increasing future burdens of MDs and SUDs, underscoring the need for regularly updated, age- and sex-specific adolescent mental health policies.
- Open Access
- 30 June 2026
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 27 (3) , 47274
Diagnostic Differentiation Between Unipolar and Bipolar Depression: A Machine Learning Analysis of Demographic and Clinical Features
Background: Differentiating between bipolar depression (BD) and unipolar depression (UD) presents a significant clinical challenge. Identifying the potential clinical features that distinguish between these two disorders is essential for optimizing personalized management strategies for individuals with depression. In this study, we employed machine learning to develop a classification model to distinguish between BD and UD based on demographic and clinical features. Methods: Patients with either BD or UD were included in this study. Three machine learning classifiers, including logistic regression (LR), random forest (RF), and support vector machine (SVM) were developed and compared using a dual evaluation strategy: (i) nested stratified cross-validation (5-fold outer, 3-fold inner) for unbiased model comparison; and (ii) an independent stratified hold-out split for final validation. In the latter phase, hyperparameters were optimized on the training set via grid search, with performance reported on the test set using bootstrapped 95% confidence intervals. Shapley Additive Explanations (SHAP) analysis was applied to the optimal model to elucidate feature importance. Results: A total of 449 patients (239 UD and 210 BD) were included. All three models achieved a consistent area under the receiver operating characteristic curve (ROC-AUC) of approximately 0.78, indicating moderate discriminative capacity, with the RF model demonstrating a more balanced error distribution. The top six predictive features were: family history, age, sleep disturbance (Patient Health Questionnaire-9 [PHQ9] item 3), fatigue (PHQ9 item 4), use of sleep medication (Pittsburgh Sleep Quality Index [PSQI] item 6), and suicidal ideation (PHQ9 item 9). The SHAP analysis suggested that younger age, “uncertain/unknown” family history, and the use of sleep medication tended to push predictions toward BD, whereas suicidal ideation, sleep disturbance, and fatigue tended to push predictions toward UD. Conclusions: Our machine learning approach identified key predictors—including age, family history, and sleep-related symptoms—to differentiate UD from BD in adolescent and young adult patients. Although achieving moderate accuracy, the model may serve as a supportive screening tool to enhance clinical decision-making.
- 30 June 2026
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 27 (3) , 47274
Open AccessDiagnostic Differentiation Between Unipolar and Bipolar Depression: A Machine Learning Analysis of Demographic and Clinical Features
Background: Differentiating between bipolar depression (BD) and unipolar depression (UD) presents a significant clinical challenge. Identifying the potential clinical features that distinguish between these two disorders is essential for optimizing personalized management strategies for individuals with depression. In this study, we employed machine learning to develop a classification model to distinguish between BD and UD based on demographic and clinical features. Methods: Patients with either BD or UD were included in this study. Three machine learning classifiers, including logistic regression (LR), random forest (RF), and support vector machine (SVM) were developed and compared using a dual evaluation strategy: (i) nested stratified cross-validation (5-fold outer, 3-fold inner) for unbiased model comparison; and (ii) an independent stratified hold-out split for final validation. In the latter phase, hyperparameters were optimized on the training set via grid search, with performance reported on the test set using bootstrapped 95% confidence intervals. Shapley Additive Explanations (SHAP) analysis was applied to the optimal model to elucidate feature importance. Results: A total of 449 patients (239 UD and 210 BD) were included. All three models achieved a consistent area under the receiver operating characteristic curve (ROC-AUC) of approximately 0.78, indicating moderate discriminative capacity, with the RF model demonstrating a more balanced error distribution. The top six predictive features were: family history, age, sleep disturbance (Patient Health Questionnaire-9 [PHQ9] item 3), fatigue (PHQ9 item 4), use of sleep medication (Pittsburgh Sleep Quality Index [PSQI] item 6), and suicidal ideation (PHQ9 item 9). The SHAP analysis suggested that younger age, “uncertain/unknown” family history, and the use of sleep medication tended to push predictions toward BD, whereas suicidal ideation, sleep disturbance, and fatigue tended to push predictions toward UD. Conclusions: Our machine learning approach identified key predictors—including age, family history, and sleep-related symptoms—to differentiate UD from BD in adolescent and young adult patients. Although achieving moderate accuracy, the model may serve as a supportive screening tool to enhance clinical decision-making.
- Open Access
- 22 June 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1) , 480
Correction: The correlations between napping and subjective sleep and daytime functioning in Chinese insomnia patients: a large-scale real-world study
- 22 June 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1) , 480
Open AccessCorrection: The correlations between napping and subjective sleep and daytime functioning in Chinese insomnia patients: a large-scale real-world study
- Open Access
- 29 April 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Effects of a phone-based, CBT-I–centered digital intervention on sleep and depressive symptoms in real-world clinical settings
This study aimed to investigate Item s associated with treatment response to a phone-based, CBT-I-centered digital intervention in patients with depressive disorders, with a primary focus on sleep-related improvement and its association with changes in depressive symptoms. A total of 307 outpatients with depressive disorders were enrolled from a sleep disorders clinic and received a phone-based, CBT-I-centered digital intervention delivered via a mobile application, in addition to routine pharmacotherapy. The intervention primarily targeted sleep disturbances and incorporated CBT techniques and psychoeducation. Participants completed demographic questionnaires and were assessed using the Pittsburgh Sleep Quality Index (PSQI), Patient Health Questionnaire-9(PHQ-9), Patient Health Questionnaire-15 (PHQ-15), and Epworth Sleepiness Scale (ESS).Treatment response was defined as a ≥ 50% reduction in total PHQ-9 score. Item s influencing treatment response at weeks 8 and 12, as well as Item s associated with residual symptoms at week 12, were analyzed. Univariate analyses showed that age and education level were significantly associated with treatment response at both weeks 8 and 12 (P < 0.05), whereas gender was not. Multivariate logistic regression indicated that younger age (< 30 years) and longer disease duration (> 3 years) were independently associated with poorer treatment outcomes at both follow-up points.At week 12, residual symptoms were significantly associated with younger age, longer disease duration, poorer sleep quality (higher PSQI scores), greater somatic symptom burden (PHQ-15), and increased daytime sleepiness (ESS).Multivariate analyses identified younger age, longer disease duration, and family history of depression as independent risk Item s for residual symptoms. This real-world study suggests that a CBT-I-centered digital intervention primarily targeting sleep disturbances may be associated with concurrent improvements in depressive symptoms among patients with depression. Younger patients and those with longer illness duration appear to be at higher risk for poorer outcomes and persistent residual symptoms. ChiCTR2500103629.
- 29 April 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessEffects of a phone-based, CBT-I–centered digital intervention on sleep and depressive symptoms in real-world clinical settings
This study aimed to investigate Item s associated with treatment response to a phone-based, CBT-I-centered digital intervention in patients with depressive disorders, with a primary focus on sleep-related improvement and its association with changes in depressive symptoms. A total of 307 outpatients with depressive disorders were enrolled from a sleep disorders clinic and received a phone-based, CBT-I-centered digital intervention delivered via a mobile application, in addition to routine pharmacotherapy. The intervention primarily targeted sleep disturbances and incorporated CBT techniques and psychoeducation. Participants completed demographic questionnaires and were assessed using the Pittsburgh Sleep Quality Index (PSQI), Patient Health Questionnaire-9(PHQ-9), Patient Health Questionnaire-15 (PHQ-15), and Epworth Sleepiness Scale (ESS).Treatment response was defined as a ≥ 50% reduction in total PHQ-9 score. Item s influencing treatment response at weeks 8 and 12, as well as Item s associated with residual symptoms at week 12, were analyzed. Univariate analyses showed that age and education level were significantly associated with treatment response at both weeks 8 and 12 (P < 0.05), whereas gender was not. Multivariate logistic regression indicated that younger age (< 30 years) and longer disease duration (> 3 years) were independently associated with poorer treatment outcomes at both follow-up points.At week 12, residual symptoms were significantly associated with younger age, longer disease duration, poorer sleep quality (higher PSQI scores), greater somatic symptom burden (PHQ-15), and increased daytime sleepiness (ESS).Multivariate analyses identified younger age, longer disease duration, and family history of depression as independent risk Item s for residual symptoms. This real-world study suggests that a CBT-I-centered digital intervention primarily targeting sleep disturbances may be associated with concurrent improvements in depressive symptoms among patients with depression. Younger patients and those with longer illness duration appear to be at higher risk for poorer outcomes and persistent residual symptoms. ChiCTR2500103629.
- Open Access
- 18 March 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
The correlations between napping and subjective sleep and daytime functioning in Chinese insomnia patients: a large-scale real-world study
This study aims to explore the associations between napping and subjective sleep quality and daytime functioning in insomnia patients, providing a valuable
- 18 March 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessThe correlations between napping and subjective sleep and daytime functioning in Chinese insomnia patients: a large-scale real-world study
This study aims to explore the associations between napping and subjective sleep quality and daytime functioning in insomnia patients, providing a valuable
- Open Access
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 3450989
Efficacy and Safety of Jiawei Suanzaoren Decoction Combined with Lorazepam for Chronic Insomnia: A Parallel‐Group Randomized Controlled Trial
Background. Chronic insomnia is a major public health problem, but there are limited effective therapies. Jiawei Suanzaoren Decoction (JW‐SZRD) has been used as an alternative option for treating insomnia. This study aimed to investigate the long‐term efficacy and safety of JW‐SZRD in combination with lorazepam for chronic insomnia. Methods. A total of 207 participants were analyzed in this study. The treatment group (TG) received JW‐SZRD and lorazepam orally, and the control group (CG) received lorazepam alone. The Insomnia Severity Index (ISI), the Self‐Rating Depression Scale (SDS), the Self‐Rating Anxiety Scale (SAS), and the Somatic Self‐rating Scale (SSS) were evaluated at baseline, weeks 4, 8, and 12. The MOS 36‐item Short Form Health Survey (SF‐36) was assessed at baseline and week 12. Adverse effects (AEs) were evaluated by the Treatment Emergent Symptom Scale (TESS). Results. Both TG and CG showed obvious improvements in the sleep onset latency (SOL) (P = 0.001 and 0.005) and total sleep time (TST) (P = 0.0001 and 0.001). However, TG was more effective than CG at weeks 8 (P = 0.02 for SOL, P = 0.008 for TST) and 12 (P = 0.03 for SOL, P = 0.04 for TST), especially in shortening SOL (Cohen’s d = 1.28). The ISI reduction rate in TG was higher than that in CG at weeks 4, 8, and 12 (P = 0.008, 0.001 and 0.001). After treatment, TG had lower SAS scores (P = 0.0001, 0.007), less somatic symptoms (P < 0.05 or 0.01), higher SF‐36 scores (P < 0.05 or 0.01), better compliance (P = 0.0001), and less adverse effects (P < 0.05 or 0.01) than those in CG. Conclusion. The combination of JW‐SZRD with lorazepam can significantly improve sleep quality with fewer AEs. It is an effective treatment and superior to lorazepam alone for chronic insomnia.
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 3450989
Open AccessEfficacy and Safety of Jiawei Suanzaoren Decoction Combined with Lorazepam for Chronic Insomnia: A Parallel‐Group Randomized Controlled Trial
Background. Chronic insomnia is a major public health problem, but there are limited effective therapies. Jiawei Suanzaoren Decoction (JW‐SZRD) has been used as an alternative option for treating insomnia. This study aimed to investigate the long‐term efficacy and safety of JW‐SZRD in combination with lorazepam for chronic insomnia. Methods. A total of 207 participants were analyzed in this study. The treatment group (TG) received JW‐SZRD and lorazepam orally, and the control group (CG) received lorazepam alone. The Insomnia Severity Index (ISI), the Self‐Rating Depression Scale (SDS), the Self‐Rating Anxiety Scale (SAS), and the Somatic Self‐rating Scale (SSS) were evaluated at baseline, weeks 4, 8, and 12. The MOS 36‐item Short Form Health Survey (SF‐36) was assessed at baseline and week 12. Adverse effects (AEs) were evaluated by the Treatment Emergent Symptom Scale (TESS). Results. Both TG and CG showed obvious improvements in the sleep onset latency (SOL) (P = 0.001 and 0.005) and total sleep time (TST) (P = 0.0001 and 0.001). However, TG was more effective than CG at weeks 8 (P = 0.02 for SOL, P = 0.008 for TST) and 12 (P = 0.03 for SOL, P = 0.04 for TST), especially in shortening SOL (Cohen’s d = 1.28). The ISI reduction rate in TG was higher than that in CG at weeks 4, 8, and 12 (P = 0.008, 0.001 and 0.001). After treatment, TG had lower SAS scores (P = 0.0001, 0.007), less somatic symptoms (P < 0.05 or 0.01), higher SF‐36 scores (P < 0.05 or 0.01), better compliance (P = 0.0001), and less adverse effects (P < 0.05 or 0.01) than those in CG. Conclusion. The combination of JW‐SZRD with lorazepam can significantly improve sleep quality with fewer AEs. It is an effective treatment and superior to lorazepam alone for chronic insomnia.
- Open Access
- 1 January 2017
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2017 (1) , 8391637
Modified Suanzaorentang Had the Treatment Effect for Generalized Anxiety Disorder for the First 4 Weeks of Paroxetine Medication: A Pragmatic Randomized Controlled Study
Background. Paroxetine does not show satisfactory therapeutic effect for generalized anxiety disorder (GAD) patients for the first 2–4 weeks of medication. Diazepam is always concurrently used although it has some shortcomings such as physical dependence and withdrawal reactions. In this study, we aimed to identify whether modified Suanzaorentang (MSZRT), a combined Chinese formula including Suanzaorentang (SZRT) and Zhizichitang (ZZCT), could control the anxiety of GAD for the first 4 weeks of paroxetine medication. Methods. 156 GAD patients were randomized to the treatment of paroxetine, paroxetine‐diazepam, or paroxetine‐MSZRT for 4 weeks. Hamilton Anxiety Scale (HAMA) Test and Self‐Rating Anxiety Scale (SAS) Test were determined each week as the evaluation of clinical efficacy. Adverse events (AEs) were also closely observed by performing the Treatment Emergent Symptom Scale (TESS) Test. Results. Both paroxetine‐MSZRT and paroxetine‐diazepam decreased more HAMA and SAS total scores than paroxetine from weeks 1 to 3. Paroxetine‐MSZRT as well as paroxetine‐diazepam had an obviously higher onset rate than paroxetine in each week. After 4 weeks’ treatment, the overall effectiveness rate in the paroxetine‐MSZRT group (90.00%) was obviously higher than those of the paroxetine group (74.42%) but did not significantly differ from the paroxetine‐diazepam group (93.88%). Conclusion. MSZRT had the treatment effect for GAD when paroxetine was used for the first 4 weeks.
- 1 January 2017
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2017 (1) , 8391637
Open AccessModified Suanzaorentang Had the Treatment Effect for Generalized Anxiety Disorder for the First 4 Weeks of Paroxetine Medication: A Pragmatic Randomized Controlled Study
Background. Paroxetine does not show satisfactory therapeutic effect for generalized anxiety disorder (GAD) patients for the first 2–4 weeks of medication. Diazepam is always concurrently used although it has some shortcomings such as physical dependence and withdrawal reactions. In this study, we aimed to identify whether modified Suanzaorentang (MSZRT), a combined Chinese formula including Suanzaorentang (SZRT) and Zhizichitang (ZZCT), could control the anxiety of GAD for the first 4 weeks of paroxetine medication. Methods. 156 GAD patients were randomized to the treatment of paroxetine, paroxetine‐diazepam, or paroxetine‐MSZRT for 4 weeks. Hamilton Anxiety Scale (HAMA) Test and Self‐Rating Anxiety Scale (SAS) Test were determined each week as the evaluation of clinical efficacy. Adverse events (AEs) were also closely observed by performing the Treatment Emergent Symptom Scale (TESS) Test. Results. Both paroxetine‐MSZRT and paroxetine‐diazepam decreased more HAMA and SAS total scores than paroxetine from weeks 1 to 3. Paroxetine‐MSZRT as well as paroxetine‐diazepam had an obviously higher onset rate than paroxetine in each week. After 4 weeks’ treatment, the overall effectiveness rate in the paroxetine‐MSZRT group (90.00%) was obviously higher than those of the paroxetine group (74.42%) but did not significantly differ from the paroxetine‐diazepam group (93.88%). Conclusion. MSZRT had the treatment effect for GAD when paroxetine was used for the first 4 weeks.